Drug Overview
Copiktra (duvelisib; Verastem/Yakult Honsha) is a highly selective small molecule inhibitor of the p110-delta and p110-gamma isoforms of the phosphoinositide 3-kinase (PI3K) enzyme. The PI3K-delta and PI3K-gamma enzymes are preferentially expressed in leukocytes, where they are responsible for the regulation of cell proliferation, cell migration, and cell activation. The inhibitory function of Copiktra blocks the growth and survival of malignant B cells.
Analyst Outlook
Copiktra (duvelisib; Verastem/Yakult Honsha) is a small molecule inhibitor targeting the phosphoinositide 3-kinase (PI3K) enzyme approved for the treatment of relapsed/refractory chronic lymphocytic leukemia (CLL) after at least two prior therapies. Results from the Phase III DUO trial revealed that heavily pretreated patients treated with Copiktra exhibited superior median progression-free survival (PFS) versus treatment with Arzerra (ofatumumab; Genmab/Novartis). Notably, patients with 17p deletion (del17p) CLL also exhibited responses to Copiktra. The presence of del17p is the strongest adverse prognostic factor for survival in CLL patients, and patients with this chromosomal abnormality remain an area of high unmet need. Ongoing Copiktra clinical trials continue to investigate the drug’s safety and efficacy in relapsed/refractory CLL, and several early-phase trials suggest that Verastem is looking to target the first-line setting
Copiktra (duvelisib; Verastem/Yakult Honsha) is a highly selective small molecule inhibitor of the p110-delta and p110-gamma isoforms of the phosphoinositide 3-kinase (PI3K) enzyme. The PI3K-delta and PI3K-gamma enzymes are preferentially expressed in leukocytes, where they are responsible for the regulation of cell proliferation, cell migration, and cell activation. The inhibitory function of Copiktra blocks the growth and survival of malignant B cells.
Analyst Outlook
Copiktra (duvelisib; Verastem/Yakult Honsha) is a small molecule inhibitor targeting the phosphoinositide 3-kinase (PI3K) enzyme approved for the treatment of relapsed/refractory chronic lymphocytic leukemia (CLL) after at least two prior therapies. Results from the Phase III DUO trial revealed that heavily pretreated patients treated with Copiktra exhibited superior median progression-free survival (PFS) versus treatment with Arzerra (ofatumumab; Genmab/Novartis). Notably, patients with 17p deletion (del17p) CLL also exhibited responses to Copiktra. The presence of del17p is the strongest adverse prognostic factor for survival in CLL patients, and patients with this chromosomal abnormality remain an area of high unmet need. Ongoing Copiktra clinical trials continue to investigate the drug’s safety and efficacy in relapsed/refractory CLL, and several early-phase trials suggest that Verastem is looking to target the first-line setting
Table of Contents
OVERVIEW
LIST OF FIGURES
LIST OF TABLES
